16 January 2018 - There is no affordability crisis to justify expanding drug price regulation, or a new national government-run pharmacare monopoly.
Health policy in Canada is not evidence-based. For proof, look no further than the new drug-price regulations being implemented by the federal government, and its ongoing consideration of a new public monopoly drug-insurance program known as Pharmacare. The cost of patented drugs is the phony excuse driving both.
The government recently announced new rules that will arbitrarily regulate a lower ceiling price for patented drugs — even though its own data show that current prices have grown slower than inflation, and are below the median of comparable countries.